Video B-Roll Via Satellite - First study to show positive benefit on atherosclerosis for people with early signs of diseased arteries



    METEOR trial shows CRESTOR slowed progression of atherosclerosis compared
    to baseline in people at low-risk of coronary heart disease
    (Framingham 10 year risk (less than)10%)

    TORONTO, March 26 /CNW/ - The following B-Roll is available at the listed
times and co-ordinates:

    
    Live Satellite Coordinates:

      DATE OF FEED: Monday, March 26, 2007

      TIME OF FEED: 11:00 - 11:30 am EDT

      COORDINATES:  Anik F2 C Band
                    Transponder 6B
                    Downlink Frequency 3940 vertical
                    Audio subcarrier 6.2 and 6.8
    

    STORY SUMMARY: METEOR (Measuring Effects on intima media Thickness: an
Evaluation Of Rosuvastastin) is the first study to show a positive effect on
atherosclerosis in people with early signs of carotid artery disease and low
risk of coronary heart disease (CHD). The METEOR study, using CRESTOR(TM)
(rosuvastatin) 40 mg, slowed progression of atherosclerosis compared to
baseline and showed significantly slower progression compared to placebo over
the two year duration of the study.

    
    Key findings from METEOR:

    -  CRESTOR achieved a -0.0014 mm/yr change in CIMT at all sites, compared
       to +0.0131 mm/yr with placebo (p(less than)0.0001) - primary endpoint
    -  CRESTOR achieved significant regression in the common carotid artery
       (-0.0038 mm/yr vs. +0.0084 mm/yr with placebo (p(less than)0.0001))
       - secondary endpoint
    -  CRESTOR achieved a +0.0039 mm/yr change in CIMT in the internal
       carotid artery vs. +0.0145 mm/yr with placebo (p=0.023) -
       secondary endpoint
    -  CRESTOR demonstrated a -0.0040 mm/yr change in CIMT in the carotid
       bifurcation (bulb) sites, compared to +0.0172 mm/yr with placebo
       (p(less than)0.0001) - secondary endpoint
    -  These changes were associated with a 48.8 percent reduction in
       LDL-C (p(less than)0.0001) and an 8.0 percent increase in
       HDL-C (p(less than)0.0001)
    -  CRESTOR 40 mg over 2 years was well tolerated during the study
    

    STATIONS, FOR FURTHER INFORMATION, PLEASE CALL:
    Dara Willis, Fleishman-Hillard Canada, (416) 645-8179.

    For technical information DURING the feed, please call CNW at
    (416) 294-9180.

    As with all CNW Broadcast feeds, this release is offered for your free
and unrestricted news use. Comments regarding the content and quality are
welcomed.





For further information:

For further information: CNW BROADCAST, TORONTO (416) 863-9350


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890